Gainers
- TFF Pharmaceuticals TFFP stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The company's market cap stands at $9.1 million.
- Centene CNC stock rose 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the news, the Q3 earnings report came out today.
- Nexalin Technology NXL shares rose 9.31% to $2.35. The market value of their outstanding shares is at $24.8 million.
- Citius Oncology CTOR shares increased by 8.76% to $1.31. The company's market cap stands at $93.4 million.
- Actinium Pharma ATNM shares increased by 8.33% to $1.82. The company's market cap stands at $56.7 million.
- BioVie BIVI shares rose 8.11% to $2.93. The market value of their outstanding shares is at $23.3 million.
Losers
- Monopar Therapeutics MNPR stock fell 23.9% to $24.85 during Friday's pre-market session. The company's market cap stands at $87.4 million.
- Quince Therapeutics QNCX stock declined by 15.97% to $1.0. The company's market cap stands at $43.2 million.
- Bionomics BNOX stock declined by 14.89% to $0.31. The market value of their outstanding shares is at $4.0 million.
- Hepion Pharmaceuticals HEPA shares decreased by 11.01% to $0.65. The company's market cap stands at $3.7 million.
- Dogwood Therapeutics DWTX stock fell 10.11% to $4.27. The market value of their outstanding shares is at $5.6 million.
- Passage Bio PASG shares decreased by 9.91% to $0.58. The market value of their outstanding shares is at $35.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BIVIBioVie Inc
$3.05-1.61%
BNOXBionomics Ltd
$0.31002.79%
CNCCentene Corp
$60.370.52%
CTORCitius Oncology Inc
$1.2724.5%
DWTXDogwood Therapeutics Inc
$2.492.47%
HEPAHepion Pharmaceuticals Inc
$0.6300-%
MNPRMonopar Therapeutics Inc
$22.311.35%
NXLNexalin Technology Inc
$4.03-1.83%
PASGPassage Bio Inc
$0.9555-5.40%
QNCXQuince Therapeutics Inc
$2.03-2.40%
TFFPTFF Pharmaceuticals Inc
$0.32310.34%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in